The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF® network review
2019
Summary Patients with radioiodine-refractory (RAIR) differentiated thyroid carcinoma (DTC) represent a challenging subgroup of DTC because they are at higher risk of cancer-related death. Multidisciplinary discussions can assess the role and the nature of local treatments, but also determine the optimal timing for first-line antiangiogenic therapy as some of these patients can be followed for several months or years without any treatment. In this review, we will examine the definition of RAIR-DTC, the different treatment options and finally some of the most recent cancer research breakthroughs for RAIR-DTC.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
59
References
5
Citations
NaN
KQI